ZGF Architects’ Post

𝐄𝐦𝐩𝐨𝐰𝐞𝐫𝐢𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐩𝐚𝐭𝐞𝐧𝐭 𝐤𝐧𝐨𝐰𝐥𝐞𝐝𝐠𝐞! 👇 As medical science reduces mortality from many other diseases, the incidence of cancer is expected to increase rapidly because of ageing populations, unhealthy lifestyles and unfavourable environmental conditions. Innovation in technologies for fighting cancer is essential to address this challenge. The European Patent Office just launched a new “Technologies combatting cancer” platform. It offers user-friendly access to over 130 prepared searches. Thanks to EPO's expert patent examiners who have crafted advanced search strategies, accessing the most relevant patent documents for cancer technologies is now an effortless process. Start exploring now: https://lnkd.in/eMpx7t-C #FightCancer #CancerAwareness #InnovationInHealthcare #WorldCancerDay

Happy to share our collaborative research with SK Life Science Labs, on the selective and orally efficacious SMARCA2 degraders at #AACR "Abstract 4506: Abstract 4506: Discovery of potent, highly selective and orally efficacious SMARCA2 degraders Link for the abstract: https://lnkd.in/gZYvdS52

Researchers have been able to better identify the different subtypes of #nccRCC to provide effective treatment, which was the focus of a presentation by Laurence Albiges, MD, PhD, during #KCRS24. https://lnkd.in/edZ8tkr7

"Nearly 100 years after the discovery of penicillin, we're on the brink of a "post-antibiotic era, with rising levels of bacteria resistant to even our last resort antibiotics." When it comes to advancing the future of medical therapies, solutions are often far from simple, but that's not stopping Professor Lara Malins from the ANU Research School of Chemistry. And her achievements are not going unnoticed. Professor Malin's work has been awarded a prestigious $8 million fellowship from Snow Medical to help in her fight against some of the globe's most pressing health challenges, including antimicrobial resistance and cancer, and to advance new life-saving medical therapies. Read more about her inspiring work: https://lnkd.in/gwf87YG8

We are only six months from the 12th Annual Cholangiocarcinoma Foundation Conference, "International Consensus on Research Priorities." Please save the date: April 9-11, 2025. This year’s Conference is an effort between CCF’s International Cholangiocarcinoma Research Network (ICRN) and the European Cooperation in Science and Technology (COST)-Action: Precision-BTC-Network, part of the European Network for the Study of Cholangiocarcinoma (ENS-CCA) to focus research priorities for cholangiocarcinoma. The initiative brings together patients, caregivers, advocates, oncologists, scientists, industry, young investigators, regulators, and other specialists worldwide to review scientific evidence, share insights, and reach a consensus, or full agreement, on the research focus going forward to optimize existing and attract new funding. Learn more and sign up to receive updates here: https://lnkd.in/eY-hv6HV

Great news! 🎉 The Ubbo Emmius Foundation (UEF) has funded HTRIC €18.4 million euros. This funding supports innovative research in health technology and strengthens the Northern Netherlands as a leading region in this field. Being a partner of HTRIC we are very happy with this development. Our dean Wiro Niessen says: “This investment enables us to accelerate realizing our ambition: a healthier future for all. HTRIC combines science, technology and practice to bring medical innovations to patients quickly and effectively.” With a focus on research themes such as molecular diagnostics, imaging, targeted therapy, and materials, HTRIC aims to create impactful solutions like light-activated cancer therapy and minimally invasive implants. These advancements bring us closer to safer, more effective, and personalized patient care. #HealthTech #Innovation #Collaboration #HTRIC #UMCG #UbboEmmiusFoundation 

A major new study revealed that Gen X faces higher cancer rates than any previous generation. In a recent article from Scientific American, researchers are investigating the potential contributing factors to this alarming trend. In the article, Dr. Andrew Chan of Harvard Medical School noted, “It’s very clear to us that cancer is evolving from a disease which has traditionally been considered a disease of aging to one which affects, really, all age groups. We need to develop more precision prevention approaches where we start to understand better who’s at risk in the general population and to start to target our efforts more directly to those people to make more headway.” That’s why one of our key priorities is to fuel research for this exact purpose: if we can better identify who is at risk and then intervene with targeted prevention methods, we can effectively slow--and ultimately one day reverse--incidence trends. https://bit.ly/3xTvAJT

ASIA 2024 PRECOURSES - REGISTER NOW! Researchers, Clinicians, and other SCI Professionals are invited to join us for the 2024 Annual Scientific Meeting, May 20-23 in San Juan, Puerto Rico. The conference will include three-and-a-half days of Precourses, Courses, General Sessions, Posters, and endless networking.  Precourse 1 DME and Accessibility: The Essence for Maintaining Autonomy and Independence of People with a Spinal Cord Injury A collaborative one-day workshop organized by three ASIA Committees (Americas, Rehabilitation Standards and Education) to enhance the knowledge of spinal cord injury care for any provider involved in the care of this patient population in the United States and abroad. Precourse 2 From Molecules to Movement – Scope, Utility, and Application of Biomarkers for SCI Clinical Trials and the Development of SCI Precision Medicine Spinal Cord Outcomes Partnership Endeavor (SCOPE) This pre-course is tailored for SCI clinicians, preclinical and clinical researchers as well as biomarker scientists

We are pleased to be sponsoring the 2024 Neuromuscular Study Group (NMSG) Annual Scientific Meeting, taking place from 20-22 September in Tarrytown, NY. Martin Brandhøj Skov, Innovation Manager, will present ‘CIC-1 inhibition improves skeletal muscle function in rat models and patients with myasthenia gravis,’ from 17:30-19:30 EDT during the Abstract Poster Session on 20 September, detailing clinical and preclinical work investigating the therapeutic potential of NMD670, our selective skeletal muscle targeted CIC-1 ion channel inhibitor. The data demonstrate the ability of CIC-1 inhibition to enhance #neuromuscular transmission and improve muscle function in both animal models of myasthenia gravis (#MG) and in patients, as well as the potential of this novel therapeutic modality to address similar symptoms in other diseases with compromised neuromuscular transmission, including spinal muscular atrophy (#SMA) and Charcot-Marie-Tooth disease (#CMT). Members of the NMD Pharma team, Dan Brennan, SVP, Corporate and Commercial Strategy, and JITENDRA GUPTE, VP, Clinical Operations, will also attend the meeting. If you are interested in learning more about our novel muscle-targeted approach for the treatment of neuromuscular disorders, please reach out to contact@nmdpharma.com to set up a meeting. For more about the #conference: https://lnkd.in/drh-jWtr #NMDPharma #Biotech #NeuromuscularDisease #Innovation #MyastheniaGravis

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has expanded its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS) to additional trial sites across the northeast US. The trial sites include Yale University, Johns Hopkins University, Cornell University, University of Buffalo, University of Massachusetts, and Thomas Jefferson University. More at #Proactive #ProactiveInvestors http://ow.ly/j2B2105QL11